389 related articles for article (PubMed ID: 31551292)
21. SGLT2i: beyond the glucose-lowering effect.
Ni L; Yuan C; Chen G; Zhang C; Wu X
Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
[TBL] [Abstract][Full Text] [Related]
22. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
[TBL] [Abstract][Full Text] [Related]
23. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
[TBL] [Abstract][Full Text] [Related]
25. New Therapeutic Strategies for Type 2 Diabetes
Yehya A; Sadhu AR
Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
[TBL] [Abstract][Full Text] [Related]
26. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
[TBL] [Abstract][Full Text] [Related]
27. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
Nassif ME; Kosiborod M
Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
[No Abstract] [Full Text] [Related]
28. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
29. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.
Gurgle HE; White K; McAdam-Marx C
Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752
[TBL] [Abstract][Full Text] [Related]
30. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Shehadeh N; Raz I; Nakhleh A
Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
[No Abstract] [Full Text] [Related]
32. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
Gao Y; Peterson E; Pagidipati N
Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
34. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
35. Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.
Arévalo-Lorido JC; Gómez JC; Huelgas RG; de Lucas DG; Polo LM; Aguilar JMV; Muñoz JE
High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):417-420. PubMed ID: 30251110
[TBL] [Abstract][Full Text] [Related]
36. The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management.
Sabouret P; Galati G; Angoulvant D; Germanova O; Castelletti S; Pathak A; Metra M; Margonato A
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):394-404. PubMed ID: 32402065
[TBL] [Abstract][Full Text] [Related]
37. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
Qiu M; Ding LL; Wei XB; Liu SY; Zhou HR
J Cardiovasc Pharmacol; 2021 Jan; 77(1):34-37. PubMed ID: 33136765
[TBL] [Abstract][Full Text] [Related]
39. Report from the 5th cardiovascular outcome trial (CVOT) summit.
Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
[TBL] [Abstract][Full Text] [Related]
40. The current landscape for diabetes treatment: Preventing diabetes-associated CV risk.
Dardano A; Bianchi C; Garofolo M; Del Prato S
Atherosclerosis; 2024 Jul; 394():117560. PubMed ID: 38688748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
